trending Market Intelligence /marketintelligence/en/news-insights/trending/CsitGZKtqqVZD-ZCnezJ8A2 content esgSubNav
In This List

Aviragen Therapeutics to reduce staff, seeking strategic alternatives

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Aviragen Therapeutics to reduce staff, seeking strategic alternatives

Aviragen Therapeutics Inc. is reducing its head count by 25% as it explores strategic alternatives of the business, including a combination or merger.

Stifel Nicolaus & Co. Inc. will advise the company during the review process.

The company said it will not proceed with the planned phase 2 trial of Vapendavir in hematopoietic stem cell transplant patients, though it continues to evaluate a potential clinical development path for the drug.

Meanwhile, top-line efficacy data from the phase 2 trial evaluating BTA074 to treat condyloma caused by human papillomavirus is expected in the first half of 2018.